VSTS vs PG

For growth investors, The Procter & Gamble Company (PG) is the stronger pick with 0.

3% revenue growth year-over-year, versus -2. 5% for Vestis Corporation (VSTS). The Procter & Gamble Company (PG) offers the better valuation at 22. 5x trailing P/E (21. 2x forward), making it the more compelling value choice. Analysts rate The Procter & Gamble Company (PG) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, The Procter & Gamble Company is actually cheaper at 21.

2x.

Over the past 5 years, The Procter & Gamble Company (PG) delivered a total return of +20.

4%, compared to -50. 9% for Vestis Corporation (VSTS). Over 10 years, the gap is even starker: PG returned +119. 7% versus VSTS's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Procter & Gamble Company (PG) is the lower-risk stock at 0.

13β versus Vestis Corporation's 1. 35β — meaning VSTS is approximately 906% more volatile than PG relative to the S&P 500. On balance sheet safety, The Procter & Gamble Company (PG) carries a lower debt/equity ratio of 68% versus 164% for Vestis Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Procter & Gamble Company (PG) is pulling ahead at 0.

3% versus -2. 5% for Vestis Corporation (VSTS). On earnings-per-share growth, the picture is similar: The Procter & Gamble Company grew EPS 8. 1% year-over-year, compared to -293. 8% for Vestis Corporation. Over a 3-year CAGR, PG leads at 1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Procter & Gamble Company (PG) is the more profitable company, earning 19.

0% net margin versus -1. 5% for Vestis Corporation — meaning it keeps 19. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PG leads at 24. 3% versus 3. 0% for VSTS. At the gross margin level — before operating expenses — PG leads at 51. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Procter & Gamble Company (PG) trades at 21.

2x forward P/E versus 22. 1x for Vestis Corporation — 0. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PG: 10. 6% to $161. 88.

All stocks in this comparison pay dividends.

The Procter & Gamble Company (PG) offers the highest yield at 2. 7%, versus 1. 1% for Vestis Corporation (VSTS).

For long-horizon retirement investors, The Procter & Gamble Company (PG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

13), 2. 7% yield, +119. 7% 10Y return). Both have compounded well over 10 years (PG: +119. 7%, VSTS: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VSTS (Industrials) and PG (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.